Search research articles
Contact Us
Filters
Showing results (1-10 of 43) with videos related to
Page
of 5
Sort By:
Oncotarget
|
February 19, 2019
A novel combined targeted therapy with bromodomain antagonist and MEK inhibitor in anaplastic thyroid cancer
Carmelo Nucera
Frontiers in Endocrinology
|
November 9, 2013
Targeting thyroid cancer microenvironment: basic research and clinical applications
Carmelo Nucera
Aging
|
August 31, 2016
Evolution of resistance to thyroid cancer therapy
Carmelo Nucera
Advances in Experimental Medicine and Biology
|
October 19, 2021
Tumor Microenvironment-Associated Pericyte Populations May Impact Therapeutic Response in Thyroid Cancer
Asumi Iesato, Carmelo Nucera
Frontiers in Endocrinology
|
June 1, 2012
Clinical outcome, role of BRAF(V600E), and molecular pathways in papillary thyroid microcarcinoma: is it an indolent cancer or an early stage of papillary thyroid cancer?
Carmelo Nucera, Alfredo Pontecorvi
Molecules (Basel, Switzerland)
|
June 2, 2021
Role of Regulatory Non-Coding RNAs in Aggressive Thyroid Cancer: Prospective Applications of Neural Network Analysis
Asumi Iesato, Carmelo Nucera
Endocrinology and Metabolism Clinics of North America
|
February 6, 2019
Coding Molecular Determinants of Thyroid Cancer Development and Progression
Veronica Valvo, Carmelo Nucera
Current Opinion in Endocrine and Metabolic Research
|
December 30, 2024
Therapeutic treatments targeting communication between angiogenic and immune microenvironments in thyroid cancers
Alessandro Prete, Carmelo Nucera
Aging
|
December 21, 2016
Effect of the micronutrient iodine in thyroid carcinoma angiogenesis
Kayla Daniell, Carmelo Nucera
The Journal of Clinical Endocrinology and Metabolism
|
October 28, 2014
Personalized therapy in patients with anaplastic thyroid cancer: targeting genetic and epigenetic alterations
Neal Smith, Carmelo Nucera
Page
of 5
Search research articles
Search
Showing results (1-10 of 43) with videos related to
Sort By:
Page
of 5
Oncotarget
|
February 19, 2019
A novel combined targeted therapy with bromodomain antagonist and MEK inhibitor in anaplastic thyroid cancer
Carmelo Nucera
Frontiers in Endocrinology
|
November 9, 2013
Targeting thyroid cancer microenvironment: basic research and clinical applications
Carmelo Nucera
Aging
|
August 31, 2016
Evolution of resistance to thyroid cancer therapy
Carmelo Nucera
Advances in Experimental Medicine and Biology
|
October 19, 2021
Tumor Microenvironment-Associated Pericyte Populations May Impact Therapeutic Response in Thyroid Cancer
Asumi Iesato, Carmelo Nucera
Frontiers in Endocrinology
|
June 1, 2012
Clinical outcome, role of BRAF(V600E), and molecular pathways in papillary thyroid microcarcinoma: is it an indolent cancer or an early stage of papillary thyroid cancer?
Carmelo Nucera, Alfredo Pontecorvi
Molecules (Basel, Switzerland)
|
June 2, 2021
Role of Regulatory Non-Coding RNAs in Aggressive Thyroid Cancer: Prospective Applications of Neural Network Analysis
Asumi Iesato, Carmelo Nucera
Endocrinology and Metabolism Clinics of North America
|
February 6, 2019
Coding Molecular Determinants of Thyroid Cancer Development and Progression
Veronica Valvo, Carmelo Nucera
Current Opinion in Endocrine and Metabolic Research
|
December 30, 2024
Therapeutic treatments targeting communication between angiogenic and immune microenvironments in thyroid cancers
Alessandro Prete, Carmelo Nucera
Aging
|
December 21, 2016
Effect of the micronutrient iodine in thyroid carcinoma angiogenesis
Kayla Daniell, Carmelo Nucera
The Journal of Clinical Endocrinology and Metabolism
|
October 28, 2014
Personalized therapy in patients with anaplastic thyroid cancer: targeting genetic and epigenetic alterations
Neal Smith, Carmelo Nucera
Page
of 5